Lv2
180 积分 2021-12-09 加入
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
17天前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
18天前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
18天前
已完结
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
22天前
已完结
[Survey on the standardization of Lung Cancer Diagnosis and Treatment in Pulmonary and Critical Care Medicine in China in 2024]
1个月前
已完结
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non-Small-Cell Lung Cancer
1个月前
已关闭
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure
2个月前
已完结
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial
3个月前
已关闭
Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead
3个月前
已完结
Informative censoring of surrogate end-point data in phase 3 oncology trials
3个月前
已完结
皖公网安备34019202002308
